COVID-19 vaccine reaches phase-2 trials in China
Xinhua |
Updated: 2020-06-20 21:11
Share
Share - WeChat
BEIJING - An inactivated COVID-19 vaccine candidate developed by the Institute of Medical Biology under the Chinese Academy of Medical Sciences has entered phase-2 clinical trials in China, the Science and Technology Daily reported Saturday.
The phase-2 trials, which further evaluate the immunogenicity and safety of the vaccine in humans, are conducted in the southwestern province of Yunnan.
So far, five COVID-19 vaccine candidates have been approved for clinical trials in China, accounting for 40 percent of the total vaccines in clinical trials worldwide, according to the Ministry of Science and Technology.
- China releases reports on budgets, national economic and social development plans
- China issues guidelines to enhance professional social work workforce
- China-Vietnam friendship exchange to strengthen bonds, security, ministry says
- Beyond the racetrack: F1 Chinese Grand Prix showcases Shanghai culture
- AWE 2026: A glance at tech for the future
- China has broken disability-poverty link, Rome seminar hears
